Ryvu Therapeutics inks deal with BioNTech to support clinical trials

Poland’s clinical-stage drug cancer focused developer Ryvu Therapeutics (WSE: RVU) is entering a strategic agreement with Germany’s BioNTech (Nasdaq: BNTX) to benefit Polish cancer patients by supporting trial site activation and patient recruitment for multiple investigational immunotherapies of BioNTech’s oncology pipeline in Poland.

The parties plan to leverage Ryvu’s operational excellence, expertise in oncology clinical operations, and existing trial site network to streamline access of Polish patients to BioNTech’s investigational immunotherapies. BioNTech intends to design and roll out clinical trials for some of the company’s priority programs in Poland and fund Ryvu’s services under the agreement. The clinical programs planned to be included in the agreement span multiple solid tumor types, including lung, breast, and colorectal cancer.

Back in 2022, the companies entered into a multi-target research collaboration for several small molecule immunotherapy programs as well as an exclusive license agreement for Ryvu’s STING agonist portfolio as standalone small molecules.